US4360681A
(en)
*
|
1973-12-03 |
1982-11-23 |
Hoffmann-La Roche Inc. |
Novel thiophene compounds
|
US4299968A
(en)
*
|
1973-12-03 |
1981-11-10 |
Hoffmann-La Roche Inc. |
Novel thiophene compounds
|
US3956315A
(en)
*
|
1974-03-21 |
1976-05-11 |
Chevron Research Company |
Herbicidal N-(3-cyano-4-alkylthien-2-yl) ureas
|
US3989505A
(en)
*
|
1975-06-23 |
1976-11-02 |
Hawaiian Sugar Planters' Association |
Use of polycyclic thiophene compounds as ripeners for sugarcane
|
US4428963A
(en)
|
1976-08-23 |
1984-01-31 |
Hoffmann-La Roche Inc. |
Novel thiophene derivatives
|
US4317915A
(en)
*
|
1976-08-23 |
1982-03-02 |
Hoffmann-La Roche Inc. |
Novel thiophene derivatives
|
DE2644425A1
(de)
*
|
1976-09-30 |
1978-04-06 |
Schering Ag |
2-(dimethylcarbamoylimino)-benzthiazolin-3-carbonsaeureester, verfahren zur herstellung dieser verbindungen sowie diese enthaltende herbizide mittel
|
DE2817449A1
(de)
*
|
1978-04-21 |
1979-10-31 |
Bayer Ag |
Mittel zur regulierung des pflanzenwachstums
|
DE3211851A1
(de)
|
1982-03-31 |
1983-10-06 |
Basf Ag |
Dihydrothiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
|
DE3305866A1
(de)
*
|
1983-02-19 |
1984-08-23 |
Basf Ag, 6700 Ludwigshafen |
Thiophen-carbonester, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
|
DE3541629A1
(de)
*
|
1985-11-26 |
1987-05-27 |
Bayer Ag |
Selektiv-fungizide verwendung von 1-(3-ethoxycarbonyl-4-ethyl-5-methyl-2-thienyl)-3-methylharnstoff
|
DE3541631A1
(de)
*
|
1985-11-26 |
1987-05-27 |
Bayer Ag |
Selektiv-fungizide verwendung von thienylharnstoff-derivaten
|
DE3541628A1
(de)
*
|
1985-11-26 |
1987-05-27 |
Bayer Ag |
Thienylharnstoff-derivate
|
US4859699A
(en)
*
|
1987-07-20 |
1989-08-22 |
Sandoz Ltd. |
Substituted N-benzoyl-N'-thienylureas
|
US6344476B1
(en)
|
1997-05-23 |
2002-02-05 |
Bayer Corporation |
Inhibition of p38 kinase activity by aryl ureas
|
US6187799B1
(en)
*
|
1997-05-23 |
2001-02-13 |
Onyx Pharmaceuticals |
Inhibition of raf kinase activity using aryl ureas
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
US20080269265A1
(en)
*
|
1998-12-22 |
2008-10-30 |
Scott Miller |
Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
RU2319693C9
(ru)
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US7371763B2
(en)
*
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
EP1769795B1
(en)
*
|
2001-12-03 |
2013-07-24 |
Bayer HealthCare LLC |
Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
|
WO2003068223A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
AU2003209118A1
(en)
*
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
CA2526636C
(en)
|
2003-05-20 |
2012-10-02 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
CL2004001834A1
(es)
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
MXPA06012394A
(es)
*
|
2004-04-30 |
2007-01-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
|